Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating rheumatoid arthritis and uses thereof

A technology for rheumatoid and arthritis, which is applied in the field of drugs for the treatment of rheumatoid arthritis, and can solve problems such as non-response of patients, difficulty in treatment, failure of secondary treatment, etc.

Inactive Publication Date: 2019-01-15
LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The treatment of RA is very difficult, so far, there is still a lack of safe and effective therapeutic drugs
Modern medicine is mainly about anti-inflammation and reducing sequelae. Drugs such as TNFα inhibitors Etanercept, Infliximab and Adalimumab can reduce some objective symptom indicators such as swelling and tender joint counts to 50% in some RA patients. Its non-response, or the failure of the second treatment, an average of about 10% of patients discontinued each year

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating rheumatoid arthritis and uses thereof
  • Medicine for treating rheumatoid arthritis and uses thereof
  • Medicine for treating rheumatoid arthritis and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example

[0020] The CIA model of DBA / 1 mice was established. DBA / 1 female mice for 6-8 weeks, after adaptive feeding for 1 week, use bovine type II collagen and complete Freund's adjuvant (BCG concentration: 4 mg / ml), after complete emulsification, inject 100 μL intradermally into the back skin near the caudal vertebra (containing 100 μg of bovine type II collagen), after 42 days, the mouse lower limbs (below the ankle joint) or upper limbs (below the wrist joint) can appear obvious redness and swelling, and the incidence rate is about 90%. 42 days after the initial immunization of DBA / 1 mice, the modeled mice were randomly divided into groups, a muscone group and a control group, with more than 10 mice in each group. In the muscone group, muscone was dissolved in 0.5% carboxymethylcellulose sodium (CMC-Na) to prepare a suspension, and in the control group, 0.5% CMC-Na was used. Muscone consumption is 40mg / kg. Oral administration, once a day, continuous treatment for 7 weeks, record ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine for treating rheumatoid arthritis, wherein the effective component is muscone, and the effective concentration is 10-1000 [mu]M. Muscone is mixed with pharmaceutically acceptable pharmaceutical adjuvants to form powders, ointments, powders, injections, aqueous solutions, enteric-coated sustained-release preparations or injections. As proved by animal experiments, that muscone can reduce joint injury and inflammatory infiltration area, bone mass defect and cartilage defect of the collagen-induced rheumatoid arthritis mice, and alleviate ankle arthritis injury. The muscone of the invention can improve the symptoms of rheumatoid arthritis. The invention also discloses the use of muscone in preparing medicines or health products for preventing and treating rheumatoid arthritis. The effective concentration of muscone is 10-1000 [mu]M.

Description

technical field [0001] The invention relates to a medicine for treating rheumatoid arthritis, and proposes the application of the medicine in preparing various forms of medicines or health food for preventing and treating rheumatoid arthritis. Background technique [0002] The prior art discloses that rheumatoid arthritis (Rheumatoid Arthritis, RA) is a chronic, systemic, progressive, autoimmune disease characterized by widespread persistent synovitis and symmetrical, destructive joint Lesions are characteristic. The treatment of RA is very difficult, so far, there is still a lack of safe and effective drugs. Modern medicine is mainly about anti-inflammation and alleviating sequelae. Drugs such as TNFα inhibitors Etanercept, Infliximab and Adalimumab can reduce some objective symptom indicators such as swelling and tender joint counts to 50% in some RA patients, but many patients still have problems in initial treatment. Its non-response, or the failure of the second treat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/122A61P19/02
CPCA23L33/00A23V2002/00A61K31/122A23V2200/30
Inventor 梁倩倩王拥军王琼徐浩施杞王晓赟陈锦漫陈涛王腾腾齐晓凤贾庆运王怡茹刘洋许崇卿刘利张利赵永见李强
Owner LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com